Article Text

PDF
CASE REPORT
Caution advised with dapagliflozin in the setting of male urinary tract outlet obstruction
  1. Victoria Hall1,
  2. Jason Kwong2,
  3. Douglas Johnson1,
  4. Elif Ilhan Ekinci3,4
  1. 1General Medicine, Austin Health, Heidelberg, Victoria, Australia
  2. 2Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
  3. 3Endocrinology, Austin Health, Heidelberg, Victoria, Australia
  4. 4Department of Medicine, Austin Health, The University of Melbourne
  1. Correspondence to Dr Victoria Hall, victoria.hall{at}austin.org.au

Summary

We describe an adverse outcome in a 70-year-old man with type 2 diabetes mellitus treated with sodium–glucose cotransporter type 2 (SGLT2) inhibitor dapagliflozin. SGLT2 inhibitors act in the proximal tubules to prevent glucose reabsorption and induce urinary glucose excretion, they have been associated with increased risk of urinary tract infection (UTI). Our patient presented to hospital with Escherichia coli septicaemia with positive urine and blood cultures on the background of two previous UTIs occurring post commencement of dapagliflozin in the community. Renal tract ultrasound in hospital revealed incomplete bladder emptying with evidence of urinary stasis, and a postvoid residual volume of 180 mL. His dapagliflozin was ceased, and he has had no further episodes of UTI. This case suggests there may be an increased risk of UTI in patients prescribed SGLT2 inhibitors who also have evidence of bladder outlet obstruction—caution is advised in the prescribing of SGLT2 inhibitors in this setting.

  • Contraindications and precautions
  • Endocrine system
  • Infections
  • Urinary and genital tract disorders
  • Urinary tract infections
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors VH researched, identified case and wrote the letter. JK helped identify case and edited the letter. DJ helped identify the case and edited the letter. EIE offered advice and edited the letter.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.